Kinetin

Kinetin

SCHEMBL458140

c1coc(CNc2[nH]cnc3ncnc2-3)c1.c1coc(CNc2[nH]cnc3ncnc2-3)c1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.54
TSHR P16473 4/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
HIF1A Q16665 2/20 0.54
ALOX15 P16050 2/20 0.54
CYP1A2 P05177 2/20 0.54
TP53 P04637 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
KDR P35968 1/20 0.54
POLB P06746 2/20 0.45
HTT P42858 6/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 5/20 0.41
MAPK1 P28482 5/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
NOD2 Q9HC29 1/20 0.41
CCNB2 O95067 2/20 0.41
CDK1 P06493 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kinetin SCHEMBL23818 1.00 SMN1; SMN2 (0.54) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL584400 0.99 SMN1; SMN2 (0.53) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL9125232 0.99 SMN1; SMN2 (0.53) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL14576216 0.93 SMN1; SMN2 (0.48) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL11692724 0.93 SMN1; SMN2 (0.48) SMN1; SMN2TSHRMEN1KMT2AHIF1A
6-Benzylaminopurine SCHEMBL1708008 0.93 SMN1; SMN2 (0.48) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL3486607 0.93 SMN1; SMN2 (0.48) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL15941490 0.93 SMN1; SMN2 (0.48) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL9811831 0.92 SMN1; SMN2 (0.47) SMN1; SMN2TSHRMEN1KMT2AHIF1A
Kinetin SCHEMBL9111320 0.90 SMN1; SMN2 (0.46) SMN1; SMN2TSHRMEN1KMT2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11357186-B2 Regeneration and genetic transformation of okra through somatic embryogenesis RASI SEEDS PRIVATE LIMITED (IN) 2022-06-14 US claimed
US-20200196549-A1 REGENERATION AND GENETIC TRANSFORMATION OF OKRA THROUGH SOMATIC EMBRYOGENESIS RASI SEEDS PRIVATE LIMITED (IN) 2020-06-25 US claimed
US-10645888-B2 Regeneration and genetic transformation of Okra through somatic embryogenesis RASI SEEDS PRIVATE LIMITED (IN) 2020-05-12 US claimed
EP-2315518-B1 SOMATIC EMBRYOGENESIS OF JATROPHA CURCAS FROM OVULES TEMASEK LIFE SCIENCES LAB LTD (SG) 2014-05-21 EP claimed
EP-0007244-B1 PREPARING NICOTINE BY CULTURING A NICOTIANA STRAIN GALLAHER LIMITED (GB) 1983-05-11 EP claimed
CN-117652414-A Tissue culture method for induction and regeneration of embryogenic callus of dendrobium candidum 中国热带农业科学院热带作物品种资源研究所 2024-03-08 CN disclosed
US-20230055908-A1 MESYLATE SALT OF PARA-TOPOLIN, COMPOSITIONS CONTAINING SAID SALT AND USE THEREOF USTAV EXPERIMENTALNI BOTANIKY AV CR, V. V. I. (CZ) 2023-02-23 US disclosed
US-20230047208-A1 RNA Splicing Modulation THE GENERAL HOSPITAL CORPORATION 2023-02-16 US disclosed
EP-3341371-B1 ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS UNIV PALACKEHO (CZ) 2022-06-29 EP disclosed
US-20220046883-A1 Methods and Compositions for Producing Cannabinoids PLURISTEM LTD. (IL) 2022-02-17 US disclosed
WO-2021233486-A1 MESYLATE SALT OF PARA-TOPOLIN, COMPOSITIONS CONTAINING SAID SALT AND USE THEREOF USTAV EXPERIMENTALNI BOTANIKY AV ČR, V. V. I. (CZ) 2021-11-25 WO disclosed
WO-2021138678-A1 RNA SPLICING MODULATION THE GENERAL HOSPITAL CORPORATION (US) 2021-07-08 WO disclosed
US-5614407-A ADMINISTERING 6-(SUBSTITUTED AMINO)PURINE CYTOKININS SENETEK PLC (US) 1997-03-25 US disclosed
US-5602139-A CONTACTING MAMMALIAN CELLS WITH A COMPOSITION CONTAINING ONE OR MORE 6-(SUBSTITUTED AMINO)PURINE CYTOKININS SENETEK PLC (US) 1997-02-11 US disclosed
EP-0696166-A1 COMPOSITION FOR TREATMENT OF PLANT MATERIAL Carstairs, Margaret Louise (GB) 1996-02-14 EP disclosed
US-5371089-A Method and composition for ameliorating the adverse effects of aging SENETEK, PLC (US) 1994-12-06 US disclosed
WO-1994024856-A1 COMPOSITION FOR TREATMENT OF PLANT MATERIAL BRITISH TECHNOLOGY GROUP LIMITED (GB) 1994-11-10 WO disclosed
EP-0317512-B1 PRODUCTIVE METHOD FOR THE REGENERATION OF COTTON FROM CULTIVATED CELLS CIBA-GEIGY AG (CH) 1992-08-05 EP disclosed
EP-0317511-A2 Insecticidal cotton plant cells CIBA-GEIGY AG (CH) 1989-05-24 EP disclosed
EP-0317512-A2 Productive method for the regeneration of cotton from cultivated cells CIBA-GEIGY AG (CH) 1989-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055908-A1 MESYLATE SALT OF PARA-TOPOLIN, COMPOSITIONS CONTAINING SAID SALT AND USE THEREOF TOP2A, TOP1, TOP2B SMN1; SMN2 2894/4885TSHR 4774/4885MEN1 942/4885
US-20230047208-A1 RNA Splicing Modulation RBM17, NSUN2, HNRNPUL2 SMN1; SMN2 267/4885TSHR 3673/4885MEN1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.